Not available
Quote | Novartis AG (NYSE:NVS)
Last: | $99.07 |
---|---|
Change Percent: | -0.89% |
Open: | $98.6 |
Close: | $99.07 |
High: | $99.19 |
Low: | $98.54 |
Volume: | 1,158,976 |
Last Trade Date Time: | 05/07/2024 03:00:00 am |
News | Novartis AG (NYSE:NVS)
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – ...
2024-05-05 14:25:00 ET There are many reasons to invest in excellent dividend stocks. Such investments are often worth the trouble regardless of whether you're investing for the dividend, or for making capital gains from the robust business (always a laudable goal). But here's the common th...
Message Board Posts | Novartis AG (NYSE:NVS)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $NVS News Article - Trading Novartis $NVS With Integrated Risk Controls | whytestocks | investorshangout | 03/10/2023 5:10:51 PM |
whytestocks: $NVS News Article - Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor | whytestocks | investorshangout | 12/09/2022 1:25:46 PM |
Former Head of Novartis Respiratory and Allergy Medicine | subslover | investorshub | 05/25/2022 1:21:42 PM |
https://www.novartis.com/news/media-releases/new-novartis-data-demonstrate-only- | FACT-MASTER | investorshub | 05/04/2022 10:57:17 PM |
https://www.novartis.com/news/media-releases/novartis-kymriah-receives-ec-approv | FACT-MASTER | investorshub | 05/04/2022 10:56:02 PM |
News, Short Squeeze, Breakout and More Instantly...
Novartis AG Company Name:
NVS Stock Symbol:
NYSE Market:
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – ...
2024-05-05 14:25:00 ET There are many reasons to invest in excellent dividend stocks. Such investments are often worth the trouble regardless of whether you're investing for the dividend, or for making capital gains from the robust business (always a laudable goal). But here's the common th...
The Federal Trade Commission (FTC) is intensifying its efforts to challenge numerous pharmaceutical patent listings, aiming to facilitate...